First-In-Human Phase 1 Study of ATNM-400, a Novel HER3-Targeting, Actinium-225 Antibody Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Actinium Pharmaceuticals Inc. published this content on October 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 19, 2026 at 17:55 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]